2025

Direct-to-Consumer Teledermatology for Male Androgenetic Alopecia: Narrative Review
Abeck F, Hansen-Abeck I, Kött J, Garrahy E, Schneider S, von Büren J
JMIR dermatology. 2025;8:e72704.

Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity
Braun L, Giesler S, Andrieux G, Riemer R, Talvard-Balland N, Duquesne S, Rückert T, Unger S, Kreutmair S, Zwick M, Follo M, Hartmann A, Osswald N, Melchinger W, Chapman S, Hutchinson J, Haferkamp S, Torster L, Kött J, Gebhardt C, Hellwig D, Karantzelis N, Wallrabenstein T, Lowinus T, Yücel M, Brehm N, Rawluk J, Pfeifer D, Bronsert P, Rogg M, Mattern S, Heikenwälder M, Fusco S, Malek N, Singer S, Schmitt-Graeff A, Ceteci F, Greten F, Blazar B, Boerries M, Köhler N, Duyster J, Ihorst G, Lassmann S, Keye P, Minguet S, Schadendorf D, Ugurel S, Rafei-Shamsabadi D, Thimme R, Hasselblatt P, Bengsch B, Schell C, Pearce E, Meiss F, Becher B, Funke-Lorenz C, Placke J, Apostolova P, Zeiser R
CANCER CELL. 2025;43(2):269-291.e19.

Retrospective multicenter analysis of real-life toxicity and outcome of ipilimumab and nivolumab in metastatic uveal melanoma
Ciernik A, Ciernik L, Bonczkowitz P, Morak M, Heinzerling L, Bennaceur Y, Lawless A, Sullivan R, Kött J, Gebhardt C, Carter T, Nathan P, Tschopp S, Dummer R, Ramelyte E
ONCOLOGIST. 2025;30(7):oyaf173.

Lehrformate zur Steigerung der Kompetenz von Medizinstudierenden beim Umgang mit Hauterkrankungen bei Skin of Color – eine Literaturübersicht
Fotohi A, Hansen-Abeck I, Heidrich I, Kött J, Schneider S, Booken N, Abeck F
DERMATOLOGIE. 2025 [Epub ahead of print].

Baseline D-dimers as predictive marker of efficacy of cemiplimab treatment in cutaneous squamous cell carcinoma
Geidel G, Adam L, Bänsch S, Fekade N, Degenhardt S, Rünger A, Kött J, Zell T, Heidrich I, Smit D, Greinert R, Volkmer B, Pantel K, Mohr P, Hauschild A, Schneider S, Gebhardt C
EUR J CANCER. 2025;226:.

Serum Complement Factor H: A Marker for Progression and Outcome Prediction Towards Immunotherapy in Cutaneous Squamous Cell Carcinoma
Geidel G, Adam L, Bänsch S, Fekade N, Deitert B, Rünger A, Kött J, Zell T, Heidrich I, Smit D, Pantel K, Schneider S, Gebhardt C
CANCERS. 2025;17(13):.

Severe overlap of morphea and lichen sclerosus after anti-PD-L1 immunotherapy in small cell lung cancer
Geidel G, Menz A, Grotenrath F, Rünger A, Kött J, Schneider S, Gebhardt C, Booken N
J DTSCH DERMATOL GES. 2025;23(3):378-380.

Characterization of non-IgA vasculitis: Demographic, clinical, and treatment-related features in a retrospective analysis of 28 biopsy-confirmed cases from a German university hospital
Hansen-Abeck I, Rünger A, Piepke L, Kött J, Giordano-Rosenbaum A, Menz A, Abeck F, Schneider S
J DERMATOL. 2025;52(1):43-49.

In-depth assessment of BRAF, NRAS, KRAS, EGFR, and PIK3CA mutations on cell-free DNA in the blood of melanoma patients receiving immune checkpoint inhibition
Heidrich I, Rautmann C, Ly C, Khatri R, Kött J, Geidel G, Rünger A, Andreas A, Hansen-Abeck I, Abeck F, Menz A, Bonn S, Schneider S, Smit D, Gebhardt C, Pantel K
J EXP CLIN CANC RES. 2025;44(1):.

Serum IL-6 is a prognostic biomarker for advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab
Kocheise L, Kempski J, Tang Y, Balcar L, Berger V, Tomczak M, Gorgulho J, Masood R, Giehren F, Schmidt C, Sutter J, Fruendt T, Pagani F, Wulf S, Kött J, Domanig S, Giannou A, Bedke T, Lücke J, Zhang T, Zhang S, Machicote A, Lohse A, Alunni-Fabbroni M, Ricke J, Khaled N, Pinter M, Scheiner B, Huber S, von Felden J, Piseddu I, Schulze K
ANN HEPATOL. 2025 [Epub ahead of print];31(1):102138.

Increase in teledermatology consultations regarding suspected tinea capitis - an observation of misidentified nevi flammei
Kött J, Dupont J, Langen K, Drerup C
J DTSCH DERMATOL GES. 2025 [Epub ahead of print].

Biomarker in der adjuvanten und neoadjuvanten Therapie des Melanoms
Kött J, Gebhardt C
DERMATOLOGIE. 2025;76(6):361-364.

Comprehensive Assessment of Prognostic Factors for Immune-Related Adverse Events in Immune Checkpoint Inhibitor-Treated Melanoma
Kött J, Merkle M, Bergmann L, Zimmermann N, Zell T, Heidrich I, Geidel G, Pantel K, Schneider S, Gebhardt C, Smit D
CANCERS. 2025;17(17):.

Improved survival of advanced melanoma patients receiving immunotherapy with concomitant antithrombotic therapy - A multicenter study on 2419 patients from the prospective skin cancer registry ADOReg
Kött J, Zell T, Zimmermann N, Rünger A, Smit D, Abeck F, Geidel G, Hansen-Abeck I, Heidrich I, Weichenthal M, Ugurel S, Leiter U, Berking C, Gutzmer R, Schadendorf D, Zimmer L, Livingstone E, Wasielewski I, Mohr P, Meier F, Haferkamp S, Drexler K, Herbst R, Kellner I, Utikal J, Wohlfeil S, Pföhler C, Adam L, Terheyden P, Ulrich J, Meiss F, Möbes M, Welzel J, Schilling B, Ziller F, Kaatz M, Kreuter A, Sindrilaru A, Dippel E, Sachse M, Weishaupt C, Hüning S, Heinzerling L, Loquai C, Schley G, Gambichler T, Löffler H, Grabbe S, Schultz E, Devereux N, Hassel J, Simon J, Raap U, Assaf C, Klemke C, Sunderkötter C, Hofmann S, Wenk S, Tronnier M, Thies S, Heppt M, Eggermont A, Schulze H, Zouboulis C, Tüting T, Bauer A, Schneider S, Gebhardt C
EUR J CANCER. 2025;214:115159.

Evaluation of S100A8/A9 and neutrophils as prognostic markers in metastatic melanoma patients under immune-checkpoint inhibition
Melzer Y, Fergen N, Mess C, Stadler J, Geidel G, Schwietzer Y, Kött J, Pantel K, Schneider S, Utikal J, Wladykowski E, Vidal-Y-Sy S, Bauer A, Gebhardt C
TRANSL ONCOL. 2025;52:102224.

Circulating tumor DNA is prognostic of patient outcome and enables therapy monitoring in metastatic uveal melanoma
Ramelyte E, Kött J, Lawless A, Ciernik A, Heidrich I, Zellweger C, Montazeri K, Mangana J, Smit D, Freiberger S, Orjuela S, Dummer R, Sullivan R, Levesque M, Gebhardt C
CLIN CANCER RES. 2025 [Epub ahead of print].

Targeting the AKT/mTOR pathway attenuates the metastatic potential of colorectal carcinoma circulating tumor cells in a murine xenotransplantation model
Smit D, Pereira-Veiga T, Brauer H, Horn M, Nissen P, Mair T, Siebels B, Voß H, Zhuang R, Haider M, Loreth D, Iskhakova M, Lindemann B, Kött J, Cayrefourcq L, Wellbrock J, Schlüter H, Pantel K, Alix-Panabières C, Jücker M
MOL ONCOL. 2025;19(10):2882-2904.

Enhanced overall and progression-free survival in advanced melanoma patients undergoing targeted therapy alongside antithrombotic treatment - Insights from a multicenter study involving 1296 patients from the prospective skin cancer registry ADOReg
Zimmermann N, Kött J, Zell T, Abedini A, Blomen C, Belz S, Deitert B, Heidrich I, Geidel G, Rünger A, Smit D, Weichenthal M, Ugurel S, Leiter U, Berking C, Gutzmer R, Schadendorf D, von Wasielewski I, Mohr P, Meier F, Herbst R, Utikal J, Terheyden P, Haferkamp S, Pföhler C, Kaatz M, Ziller F, Ulrich J, Meiss F, Bauer A, Schneider S, Gebhardt C
EUR J CANCER. 2025 [Epub ahead of print];234:116195.

2024

Patient-reported outcomes of topical finasteride/minoxidil treatment for male androgenetic alopecia: A retrospective study using telemedical data
Abeck F, Hansen I, Kött J, Schröder F, Garrahy E, Veneroso J, Rünger A, Torster L, Schneider S, von Büren J
J COSMET DERMATOL-US. 2024;23(9):2956-2963.

Sepsis-like cytokine release syndrome after application of tebentafusp in metastasized uveal melanoma
Geidel G, Abeck F, Hansen I, Kött J, Heidrich I, Rünger A, Hildebrandt L, Gebhardt C
J EUR ACAD DERMATOL. 2024;38(6):e473-e475.

Differential predictive value of tissue-specific PD-L1 expression scores in adjuvant immunotherapy of melanoma
Geidel G, Parnian N, Meß C, Schlepper N, Rünger A, Heidrich I, Hansen I, Smit D, Menz A, Pantel K, Schneider S, Kött J, Gebhardt C
J EUR ACAD DERMATOL. 2024;38(10):2017-2023.

Pegylated interferon-α2a in cutaneous T-cell lymphoma - a multicenter retrospective data analysis with 70 patients
Hansen-Abeck I, Geidel G, Abeck F, Kött J, Cankaya R, Dobos G, Mitteldorf C, Nicolay J, Albrecht J, Menzer C, Livingstone E, Mengoni M, Braun A, Wobser M, Klemke C, Tratzmiller S, Assaf C, Terheyden P, Klespe K, Schneider S, Booken N
J DTSCH DERMATOL GES. 2024;22(11):1489-1497.

Current impact of inpatient dermatological consultations at a university hospital in Germany
Hansen I, Köser C, Kött J, Schneider S, Abeck F
J DTSCH DERMATOL GES. 2024;22(5):710-712.

Successful treatment of refractory checkpoint inhibitor-induced hepatitis with quadruple therapy including extracorporeal photopheresis and infliximab
Hansen I, Kött J, Heidenreich S, Ayuk F, Doll P, Abeck F, Booken N, Gebhardt C, Schneider S
JEADV CLIN PRACT. 2024;3(1):317-320.

Prevention of amputation by neoadjuvant therapy with pembrolizumab in acrolentiginous melanoma
Hansen I, Rünger A, Noebel C, Geidel G, Kött J, Menz A, Hildebrandt L, Schneider S, Gebhardt C
J EUR ACAD DERMATOL. 2024;38(9):e820-e822.

High Serum Levels of CCL20 Are Associated with Recurrence and Unfavorable Overall Survival in Advanced Melanoma Patients Receiving Immunotherapy
Kött J, Hoehne I, Heidrich I, Zimmermann N, Reese K, Zell T, Geidel G, Rünger A, Schneider S, Pantel K, Smit D, Gebhardt C
CANCERS. 2024;16(9):.

C-reactive protein flare predicts response to checkpoint inhibitor treatment in melanoma
Kött J, Zimmermann N, Zell T, Heidrich I, Geidel G, Rünger A, Smit D, Merkle M, Parnian N, Hansen I, Hoehne I, Abeck F, Torster L, Weichenthal M, Pantel K, Schneider S, Gebhardt C
J EUR ACAD DERMATOL. 2024;38(8):1575–1587.

Sentinel lymph node risk prognostication in primary cutaneous melanoma through tissue-based profiling, potentially redefining the need for sentinel lymph node biopsy
Kött J, Zimmermann N, Zell T, Rünger A, Heidrich I, Geidel G, Smit D, Hansen I, Abeck F, Schadendorf D, Eggermont A, Puig S, Hauschild A, Gebhardt C
EUR J CANCER. 2024;202:.

Mutation analysis in individual circulating tumor cells depicts intratumor heterogeneity in melanoma
Sementsov M, Ott L, Kött J, Sartori A, Lusque A, Degenhardt S, Segier B, Heidrich I, Volkmer B, Greinert R, Mohr P, Simon R, Stadler J, Irwin D, Koch C, Andreas A, Deitert B, Thewes V, Trumpp A, Schneeweiss A, Belloum Y, Peine S, Wikman H, Riethdorf S, Schneider S, Gebhardt C, Pantel K, Keller L
EMBO MOL MED. 2024;16(7):1560-1578.

Early neuroborreliosis with leg paresis mimicking herpes zoster
Tegtmeyer J, Abeck F, Matthews H, Christolouka M, Kött J, Schmiedel S, Schneider S, Koch T
J EUR ACAD DERMATOL. 2024;38(4):e329-e330.

2023

A Rejected Hypothesis: Phenomenon of High Treatment Adherence in Direct-to-Consumer Teledermatology Despite Lack of Direct Physician-Patient Interaction
Abeck F, Hansen I, Wiesenhütter I, Brookman-May S, Sharaf K, Kött J, Bertlich M, Schneider S, von Büren J
TELEMED E-HEALTH. 2023;29(7):1051-1056.

Online Traffic Analysis of Direct-to-Consumer Websites for Hair Loss Treatment and Characterization of Finasteride Patients on a Platform in Germany: A Potential Paradigm Shift in the Treatment of Androgenetic Alopecia
Abeck F, Hansen I, Wiesenhütter I, Schröder F, Kött J, Schneider S, von Büren J
CLIN COSMET INV DERM. 2023;16:937-945.

Direct-to-Consumer Teledermatology in Germany: A Retrospective Analysis of 1,999 Teleconsultations Suggests Positive Impact on Patient Care
Abeck F, Kött J, Bertlich M, Wiesenhütter I, Schröder F, Hansen I, Schneider S, von Büren J
TELEMED E-HEALTH. 2023;29(10):1484-1491.

Neoadjuvant cemiplimab induces durable complete response in locally advanced cutaneous squamous cell carcinoma
Geidel G, Adam L, Rünger A, Menz A, Kött J, Haalck T, Gebhardt C
J EUR ACAD DERMATOL. 2023;37(12):e1414-e1416.

The potential of telemedicine for dermatological care of pediatric patients in Germany
Hansen I, Abeck D, Kött J, Schneider S, Abeck F
J DTSCH DERMATOL GES. 2023;21(2):141-145.

Letaler Verlauf einer Kryoglobulinämie Typ I
Hansen I, Ghandili S, Abeck F, Kött J, Booken N, Schneider S
J DTSCH DERMATOL GES. 2023;21(Suppl 2):15-18.

Successful Treatment of PD-1 Inhibitor-induced Psoriasis with Infliximab
Hansen I, Heidrich I, Abeck F, Kött J, Booken N, Gebhardt C, Schneider S
J EUR ACAD DERMATOL. 2023;37(5):e621-e623.

Von Willebrand factor in the plasma and in the tumor tissue predicts cancer-associated thrombosis and mortality
Karampinis I, Nowak K, Koett J, Mess C, Wagner L, Gaiser T, Mayer F, Goertz L, Schneider S, Bauer A
HAEMATOLOGICA. 2023;108(1):261-266.

Prognostic value of von Willebrand factor levels in patients with metastatic melanoma treated by immune checkpoint inhibitors
Stadler J, Keller L, Mess C, Bauer A, Koett J, Geidel G, Heidrich I, Vidal-Y-Sy S, Andreas A, Stramaglia C, Sementsov M, Haberstroh W, Deitert B, Hoehne I, Reschke R, Haalck T, Pantel K, Gebhardt C, Schneider S
J IMMUNOTHER CANCER. 2023;11(5):.

Localized monkeypox infestation in MSM on pre-exposure prophylaxis
Torster L, Tegtmeyer J, Kött J, Christolouka M, Schneider S
J EUR ACAD DERMATOL. 2023;37(3):e366-e367.

Patient-reported treatment outcomes and safety of direct-to-consumer teledermatology for finasteride treatment in male androgenetic alopecia: A cross-sectional study
von Büren J, Hansen I, Kött J, Schröder F, Veneroso J, Schneider S, Abeck F
DIGIT HEALTH. 2023;9:20552076231205740.

2022

Telemedical care of men with androgenetic alopecia demonstrates improved access to care and patient benefit
Abeck F, Kött J, Wiesenhütter I, Hiebenthal T, Hansen I, Schneider S, von Büren J
J EUR ACAD DERMATOL. 2022;36(12):e1018-e1020.

Activated Eosinophils Predict Longer Progression-Free Survival under Immune Checkpoint Inhibition in Melanoma
Ammann N, Schwietzer Y, Mess C, Stadler J, Geidel G, Kött J, Pantel K, Schneider S, Utikal J, Bauer A, Gebhardt C
CANCERS. 2022;14(22):.

Emerging precision diagnostics in advanced cutaneous squamous cell carcinoma
Geidel G, Heidrich I, Kött J, Schneider S, Pantel K, Gebhardt C
NPJ PRECIS ONCOL. 2022;6(1):.

Ungewöhnliche Lokalisation einer klassischen Dermatose
Hansen I, Kött J, Booken N, Schneider S
DERMATOLOGIE. 2022;73(11):901-903.

2021

Combination of Immune Checkpoint Inhibitors and Liver-Specific Therapies in Liver-Metastatic Uveal Melanoma: Can We Thus Overcome Its High Resistance?
Blomen C, Kött J, Hartung T, Torster L, Gebhardt C
CANCERS. 2021;13(24):.

Letzte Aktualisierung aus dem FIS: 15.01.2026 - 00:37 Uhr